Search Results for 'phase pfs'

phase pfs published presentations and documents on DocSlides.

Her-2 negative MBC
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
Blinded Sample Size Re-estimation in a Phase III Study Inve
Blinded Sample Size Re-estimation in a Phase III Study Inve
by luanne-stotts
David Morgan (King’s College, London / Consulta...
Btk  inhibition in Mantle cell Lymphoma & CLL
Btk inhibition in Mantle cell Lymphoma & CLL
by test
Simon Rule. Professor of Clinical . Haematology. ...
BELLE-3: A Phase III Study of
BELLE-3: A Phase III Study of
by faustina-dinatale
Buparlisib. and . Fulvestrant. in Postmenopausa...
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
by naomi
David Morgan (King’s College, London / Consultan...
Treatment of
Treatment of
by natalia-silvester
Biliary. Cancers. Abby B. Siegel, MD, MS . Colum...
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
by maniakti
Richard S. Finn, MD. Professor of Clinical Medicin...
GIULIANA  D’AURIA UOC Oncologia ASL Roma 2
GIULIANA D’AURIA UOC Oncologia ASL Roma 2
by hadley
Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . app...
Ovarian Cancer: Standards of Care and New Opportunities
Ovarian Cancer: Standards of Care and New Opportunities
by majerepr
Robert L. Coleman, M.D.. Professor & . Vice Ch...
Molecular Lessons Learnt from Clinical Trials in the Last Decade
Molecular Lessons Learnt from Clinical Trials in the Last Decade
by altigan
Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...
by billiontins
2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...
Romidepsin   in Association with CHOP in Patients with Peripheral T
Romidepsin in Association with CHOP in Patients with Peripheral T
by accompanypepsi
-Cell . Lymphoma: Final Results of the Phase . Ib....
 NEw developments IN  gynecological Oncology
NEw developments IN gynecological Oncology
by cheryl-pisano
highlights from the. EUROPEAN . society . of med...
 Overall Survival Benefit of
Overall Survival Benefit of
by tatyana-admore
Obinutuzumab. Over Rituximab when Combined with ...
Case Discussion: Second
Case Discussion: Second
by celsa-spraggs
Opinion. 55 year-old woman with . recurrent . ova...
State of the Art in  BRCA
State of the Art in BRCA
by ellena-manuel
-Mutated Ovarian Cancer. This program will includ...
Please note, these are the actual video-recorded proceeding
Please note, these are the actual video-recorded proceeding
by luanne-stotts
Moderator. Neil Love, MD. Mollie Moran, MSN, CNP,...
William J.
William J.
by tawny-fly
Gradishar. . MD, FACP. Betsy . Bramsen. Profess...
Department of GI Medical Oncology
Department of GI Medical Oncology
by danika-pritchard
Does . the New EPOC trial . eliminate. . Anti. -...
MEK Inhibitors and their potential role in relapsed NSCLC
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
17th Annual International Congress
17th Annual International Congress
by conchita-marotz
on . Hematologic Malignancies. ®. : . Focus . on...
ASCO 2010:
ASCO 2010:
by phoebe-click
. Highlights from the Annual Clinical Meeting. G...